Reduction in target/mean lesion size · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in reduction in target/mean lesion size compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Effectiveness · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
Clobetasol-17-propionate 0.025% lipid-loaded microspheres led to lower pain reduction (VAS 0-100) compared with conventional 0.025% clobetasol lipophilic ointment in hydrophilic…; GRADE not reported.
1 finding from 1 review
Pain intensity (0‐10cm visual analogue scale) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower pain (visual analogue scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
Donatsky 1982 (crossover, n=15, Sjogren's syndrome): CMC spray had a similar effect on oral dryness to the spray base, but was more effective than water. Paired crossover data not presented; effect size not estimable.
1 study · 15 participants
GRADE not reported
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Camomile showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Indigo wood root showed no clear difference in oral mucositis (moderate to severe) compared with saline (placebo); GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Intestinal trefoil factor showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral health (oral impacts on daily performances) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy,…
1 finding from 1 review
More in the reservoir group experienced relief of an oral impact and fewer a new impact (OIDP), but no difference in the total impact score between groups.
1 study · 86 participants
GRADE not reported
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Zinc sulphate led to lower oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Glutamine showed no clear difference in oral mucositis (any severity) compared with placebo/usual care; GRADE not reported.
1 finding from 1 review
RR 0.78 [0.57, 1.08]
5 studies
GRADE not reported
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate probably leads to lower oral mucositis (severe) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Shenqi-fanghou led to lower oral mucositis (severe) compared with no treatment; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
RR 0.74 [0.62, 0.89]
7 studies
GRADE not reported
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Histamine gel showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review